Development and Validation of a Nomogram for Predicting Survival in Gallbladder Cancer Patients With Recurrence After Surgery

Chen, Mingyu; Li, Shijie; Topatana, Win; Lv, Xiaozhong; Cao, Jiasheng; Hu, Jiahao; Jian, Lin; Juengpanich, Sarun; Shen, Jieliang; Cai, Xiujun

doi:10.3389/fonc.2020.537789

Cited by 11 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the nomograph has been extensively used as a prediction approach for oncology, which has been proved to have better predictive ability than conventional TNM classi cation 5 . In the former study 6,7 , the nomogram model showed good discrimination for patients with gallbladder cancer as well. However, to date, there haven't been studies on the nomograph prediction model of gallbladder cancer liver metastasis (GCLM).…”

Section: Introductionmentioning

confidence: 83%

Construction and Validation of the Predictive Model for Gallbladder Cancer Liver Metastasis Patients: A SEER-based Study

Zhang

Chen

2023

Preprint

View full text Add to dashboard Cite

Background The purpose of this present research was to construct a nomograph model to predict prognosis in gallbladder cancer liver metastasis (GCLM) patients so as to provide a basis for clinical decision-making. Methods We surveyed patients diagnosed with gallbladder cancer liver metastasis (GCLM) in the Surveillance Epidemiology and the End Results database (SEER) between 2010 and 2019. They were randomized 6:4 into a training set and a validation set. In the training set, statistically meaningful prognostic factors were determined using univariate and multivariate Cox regression analyses, and an individualized nomogram prediction model was generated. The prediction model was evaluated by C-index and calibration curves from the training set and the validation set. Results 727 confirmed cases were enrolled in the research, 426 in the training set and 301 in the validation set. Factors including bone-metastasis, surgery, chemotherapy and radiotherapy were independent prognostic factors for cancer specific survival (CSS) rates and were employed in the construction of the nomogram prediction model. The C-index for the training set and validation set were 0.685 and 0.709, respectively. Calibration curves indicated that the cancer specific survival (CSS) rates of the nomograph prediction model were consistent with the actual prognosis at 6-months-CSS, 1-year-CSS and 2-years-CSS in both the training set and validation set. Conclusions We have successfully constructed a nomogram prediction model that can predict cancer specific survival (CSS) rates in patients with gallbladder cancer liver metastasis (GCLM). This prediction model can help patients in counseling and guide clinicians in treatment decisions.

show abstract

Section: Introductionmentioning

confidence: 83%

Construction and Validation of the Predictive Model for Gallbladder Cancer Liver Metastasis Patients: A SEER-based Study

Zhang

Chen

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Even though surgical resection is one of the most effective treatments for GBC, more than 60% of patients suffer from postoperative recurrence within five years. [ 3 ] Furthermore, conventional chemotherapy and radiotherapy are unable to significantly prolong overall survival in patients with advanced GBC. Recently, personalized targeted therapy that focuses on the ubiquitin‐proteasome system has emerged as a promising approach for advanced GBC treatment.…”

Section: Introductionmentioning

confidence: 99%

Bortezomib‐Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy

Chen

Juengpanich

et al. 2022

Advanced Science

Self Cite

View full text Add to dashboard Cite

Gallbladder cancer (GBC) is a rare but the most malignant type of biliary tract tumor. It is usually diagnosed at an advanced stage and conventional treatments are unsatisfactory. As a proteasome inhibitor, bortezomib (BTZ) exhibits excellent antitumor ability in GBC. However, the long‐term treatment efficacy is limited by its resistance, poor stability, and high toxicity. Herein, BTZ‐encapsulated pH‐responsive copolymeric nanoparticles with estrone (ES‐NP(BTZ; Ce6)) for GBC‐specific targeted therapy is reported. Due to the high estrogen receptor expression in GBC, ES‐NP(BTZ; Ce6) can rapidly enter the cells and accumulate near the nucleus via ES‐mediated endocytosis. Under acidic tumor microenvironment (TME) and 808 nm laser irradiation, BTZ is released and ROS is generated by Ce6 to destroy the “bounce‐back” response pathway proteins, such as DDI2 and p97, which can effectively inhibit proteasomes and increase apoptosis. Compared to the traditional treatment using BTZ monotherapy, ES‐NP(BTZ; Ce6) can significantly impede disease progression at lower BTZ concentrations and improve its resistance. Moreover, ES‐NP(BTZ; Ce6) demonstrates similar antitumor abilities in patient‐derived xenograft animal models and five other types of solid tumor cells, revealing its potential as a broad‐spectrum antitumor formulation.

show abstract

“…However, GBC usually develops with insidious onset. More than 50% of patients are already at an advanced stage when the tumor is detected, making radical surgical resection difficult or even impossible ( 3 ), while the recurrence rate after surgery is not low ( 4 ). At present, palliative chemotherapy is usually considered to be the treatment option for unresectable GBC, but shows a significantly worse prognosis compared to resected GBC ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy

Yang

Xiong

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveGallbladder cancer (GBC) is highly malignant and is often diagnosed at the advanced stage. Lack of opportunity to surgery results in an unsatisfactory outcome. This pilot study employed gemcitabine combined with nab-paclitaxel (AG) as a conversion therapeutic measure for locally advanced GBC and successfully achieved conversion surgery in three initially unresectable GBC patients. We will introduce our experience on improving the outcome of this dismal disease.MethodsRadiology and nuclear medicine imaging were performed in each patient, and resectability was evaluated by joint consultation of our multi-disciplinary team (MDT). Patients evaluated as unresectable were treated with the AG regimen and re-evaluated for treatment response. When complete or partial response is achieved, MDT opinion would be required to assess the possibility of performing conversion surgery with R0 resection.ResultsThree GBC patients who were initially evaluated as unresectable successfully underwent R0 resection after conversion therapy with the AG regimen. The first case was a recurrent GBC patient evaluated as locally advanced and eventually achieved pathological complete response. The second case was a GBC patient who underwent R1 resection with residual lesions in the gallbladder bed and isolated No. 16 lymph node metastasis and who had a pathologically complete response after treatment. The third case had multiple but resectable liver metastases; both objective response and partial pathologic response were achieved. None of the patients experienced serious treatment-related adverse events. All cases revealed no evidence of recurrence or metastasis after a median follow-up of 12 months.ConclusionsConversion therapy shows a favorable efficacy in those unresectable GBC patients. Gemcitabine plus nab-paclitaxel has the potential to be used as a preoperative treatment option for GBC patients at the advanced stage. To further explore the efficacy of AG on conversion therapy for GBC patients, a prospective clinical trial has been registered (ChiCTR2200055698).

show abstract

Development and Validation of a Nomogram for Predicting Survival in Gallbladder Cancer Patients With Recurrence After Surgery

Cited by 11 publications

References 29 publications

Construction and Validation of the Predictive Model for Gallbladder Cancer Liver Metastasis Patients: A SEER-based Study

Construction and Validation of the Predictive Model for Gallbladder Cancer Liver Metastasis Patients: A SEER-based Study

Bortezomib‐Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy

Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy

Contact Info

Product

Resources

About